That's all true. But what could make it different this time. Is after 5 years of trying to perfect this new drug. All the trials are done. There is a pretty good amount of data that appears to be positive. There are four reputable companies from around the world that appear to believe this drug has the potential to save lives and make them money, that have partnered with AEZS for rights in there markets. And there is clinical data that imo is not made up. Is this data enough to gain approval? I am not sure of that, but it does have a place in the market and if it truly saves a number of lives of people who are very sick with little other chance of living longer, with a much safer profile than doxorubicin than I believe there is a 50-50 shot for us as shareholders to cash in on science. If this crappy management team doesn't f--k it up. Its up to the FDA at this point.
And the fact that we will know good or bad very soon, makes the gamble worthwhile for me at least.
News 
Market Data 
Discover 
